Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Targeting CGRP has proved to be efficacious, tolerable, and safe to treat migraine; however, many patients with migraine do not benefit from drugs that antagonize the CGRPergic system. Therefore, this review focuses on summarizing the general pharmacology of the different types of treatments currently available, which target directly or indirectly the CGRP receptor or its ligand. Moreover, the latest evidence regarding the selectivity and site of action of CGRP small molecule antagonists (gepants) and monoclonal antibodies is critically discussed. Finally, the reasons behind non-responders to anti-CGRP drugs and rationale for combining and/or switching between these therapies are addressed.

Original publication

DOI

10.1186/s10194-023-01644-8

Type

Journal article

Journal

J Headache Pain

Publication Date

11/09/2023

Volume

24

Keywords

Amylin, Anti-CGRP, Calcitonin, Headache, Migraine, Trigeminal, Humans, Antibodies, Monoclonal, Calcitonin Gene-Related Peptide Receptor Antagonists, Migraine Disorders, Receptors, Calcitonin Gene-Related Peptide, Signal Transduction